We describe the case of an acromegalic woman with primary infertility who was treated with clomiphene, and subsequently developed pituitary apoplexy.
The causes and clinical features of pituitary apoplexy are described in boxes 1 and 2. We describe a case in an acromegalic woman who was receiving clomiphene.
Case report
A 24-year-old woman presented with primary infertility. Her periods were regular every 28 days, lasting five days and menarche had occurred aged 13. She had not used oral contraceptives. Her basal serum hormone levels were: prolactin 599 mU/l, luteinising hormone (LH) 4 .7 IU/l, follicle-stimulating hormone (FSH) 3 Three days after her final tablet of clomiphene, she developed acute severe generalised headache and progressive visual impairment. Visual acuity was reduced (6/18: left eye, 6/36: right eye) with a bitemporal hemianopia and early papilloedema. Skull Xray showed an enlarged pituitary fossa and cranial computed tomography (CT) demonstrated an enhancing mass with considerable supra-sellar extension (figure).
In view of the rapid and progressive visual failure, a neurosurgical opinion was obtained and an emergency transsphenoidal decompression was performed. Necrotic and haemorrhagic debris of pituitary tumour was removed, with immediate improvement in vision postoperatively.
Endocrine assessment postoperatively revealed the clinical features of acromegaly. The diagnosis of active acromegaly was confirmed postoperatively, with elevated random growth hormone levels of > 20 mU/l (reference range < 10) and an IGF-1 level of 190 nmol/l (14-48). Serum a-subunit was not elevated (< 0.3 IU/l).
Subsequently, she underwent repeat transsphenoidal removal of residual pituitary tumour followed by external irradiation. Immunohistochemistry of pituitary tissue from the second operation was positive for growth hormone, but negative for FSH, LH, prolactin, TSH and adrenocorticotropin.
Discussion
Pituitary apoplexy, occurring in patients with pituitary tumours, has been reported following injection ofthyrotropin-releasing hormone and after combined pituitary function testing: hypoglycaemia, gonadotropin-releasing hormone (GnRH) and thyrotropin-releasing hormone. ' Box 3 Properties of clomiphene * anti-oestrogen, having a similar structure to oestradiol * acts on the hypothalamus to increase the GnRH pulse frequency resulting in increased LH (and FSH) * used in the treatment of anovulation * multiple pregnancy rate is 8% * ovarian enlargement, vasomotor flushes and abdominal-pelvic bloating are the commonest adverse effects * ovarian hyperstimulation occurs rarely * blurred vision and scintillating scotomata are reported Box 4 Learning/summary points * pituitary apoplexy is a potentially fatal condition * it may occur following clomiphene therapy in patients with pituitary adenomas * deteriorating visual acuity is an indication for urgent neurosurgical decompression Box 5 Clomiphene citrate is a long-acting antioestrogen and is used in the treatment of anovulation associated with polycystic ovarian disease and in women with normogonadotropic amenorrhoea. Its main mode ofaction is to bind to oestrogen receptors in the hypothalamus and thus increase the pulse frequency of GnRH. 9 This results in a rise in plasma levels of LH and FSH, which cause follicular development and thereby a rise in serum oestrogen levels and ovulation.
In this patient, clomiphene may have caused infarction ofthe pituitary tumour by increasing portal blood GnRH concentrations indirectly, rather than the immediate increase which would be expected after intravenous injection of GnRH.5'7 Peak plasma GnRH levels are achieved approximately 8-10 days after starting clomiphene, when given at a dose of 50 mg daily for five days.'0 The mechanism by which GnRH may cause pituitary tumour infarction is unclear but may be due to vascular spasm, portal blood being preferentially diverted to pituitary gonadotrophs under the influence of high concentrations of GnRH, with ischaemia and infarction of the somatotrophinoma. Rapid tumour expansion may have been induced by GnRH, resulting in ischaemic necrosis, although there was no evidence of increased mitosis on histological examination. Alternatively, GnRH may have acutely stimulated gonadotrophin synthesis and release, the increase in metabolic activity may have resulted in cellular hypoxia and subsequent infarction.
As far as we are aware, this is the first reported case of clomiphene-induced pituitary apoplexy. Headache and visual symptoms developing within days of clomiphene therapy in patients with pituitary tumours should raise the suspicion of pituitary apoplexy.
